Equities

Lexicon Pharmaceuticals Inc

LXRX:NSQ

Lexicon Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.8146
  • Today's Change0.043 / 5.56%
  • Shares traded3.41m
  • 1 Year change-25.95%
  • Beta1.1306
Data delayed at least 15 minutes, as of Nov 22 2024 15:11 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy2
Outperform2
Hold2
Sell0
Strong Sell0

Share price forecast in USD

The 5 analysts offering 12 month price targets for Lexicon Pharmaceuticals Inc have a median target of 4.00, with a high estimate of 10.00 and a low estimate of 1.40. The median estimate represents a 418.34% increase from the last price of 0.7717.
High1,195.8%10.00
Med418.3%4.00
Low81.4%1.40

Earnings history & estimates in USD

On Nov 12, 2024, Lexicon Pharmaceuticals Inc reported 3rd quarter 2024 losses of -0.18 per share.
The next earnings announcement is expected on Mar 10, 2025.
Average growth rate+3.47%
Lexicon Pharmaceuticals Inc reported annual 2023 losses of -0.79 per share on Mar 11, 2024.
Average growth rate-14.65%
More ▼

Revenue history & estimates in USD

Lexicon Pharmaceuticals, Inc. had 3rd quarter 2024 revenues of 1.75m. This missed the 2.93m consensus estimate of the 6 analysts following the company. This was 7,191.67% above the prior year's 3rd quarter results.
Average growth rate+111.58%
Lexicon Pharmaceuticals, Inc. had revenues for the full year 2023 of 1.20m. This was 766.19% above the prior year's results.
Average growth rate+130.38%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.